| Today's Big NewsApr 4, 2023 |
| By Annalee Armstrong Gossamer is ending development of a lymphoma med after reports of two deaths and other serious adverse events in a phase 2 trial that was paused in March citing the “benefit/risk profile observed to date.” |
|
|
|
By Max Bayer Cure Ventures has unveiled its inaugural $350 million fund, exceeding expectations as the company looks to drive forth a seed-round-focused investment strategy. The firm is led by three seasoned biotech and pharma investors, with dozens of years of combined experience. |
By Gabrielle Masson French pharma Pierre Fabre is offering up $553 million in biobucks to work with Scorpion Therapeutics on developing and potentially commercializing two of the biotech’s preclinical candidates. |
By Annalee Armstrong Oncternal Therapeutics’ pursuit of the BTK inhibitor market has come to an end after the company took a critical look at the prospects of commercial success for its blood cancer treatment. |
By Annalee Armstrong With an eye towards someday developing a “functional cure” for hepatitis B, VBI Vaccines is triaging the rest of its programs and sending 30-35% of staff out the door. |
By Nick Paul Taylor Freeline Therapeutics staffers could be forgiven for starting to dread quarterly financial results. Three months after disclosing plans to cut ties to 30 employees, the gene therapy biotech has outlined another round of layoffs and the narrowing of its pipeline focus in its fourth-quarter results. |
By Nick Paul Taylor OncoSec Medical’s six-year pursuit of potentially pivotal data on its Keytruda combination has delivered a last-minute twist. After touting an 18.8% investigator-assessed response rate, the biotech has revealed that the final result per blinded independent central review (BICR) fell well short of the bar for success. |
By Annalee Armstrong Sumitomo Pharma is doing a little bit of spring cleaning to bring a handful of biopharma units under one consolidated company to be named Sumitomo Pharma America. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By James Waldron It seems like every week brings another potential avenue to explore in combating Alzheimer's. The most recent update comes courtesy of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, which pinpointed a brain protein that could offer a fresh target. |
By Fraiser Kansteiner While Merck & Co.’s Seagen buyout wasn't fated to be, the companies’ clinical courtship in cancer has blossomed into a swift approval at the FDA. |
By Conor Hale Using a six-second video clip, Butterfly's software aims to spot the signs of excess wetness in the lungs that can hinder the ability to breathe. |
By Fraiser Kansteiner Eisai's new Leqembi analyses, which debuted at the 2023 annual meeting of the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), offer more context around the tough conversations patients and caregivers may need to have with their doctors before going on treatment. Plus, the new data will inform Eisai’s bid to translate its speedy green light into a full, traditional FDA approval. |
By Conor Hale The DNA sequencing giant now has six months to completely divest its holdings in the company. The $8 billion acquisition deal closed in August 2021 before receiving a final sign-off from regulators. Illumina has maintained that it has kept Grail’s operations at arms’ length. |
By Robert King Average premiums for Affordable Care Act plans increased by more than 3% for 2023 as the rate of new insurer entrants slowed, a report found. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss how 2023 is shaping up to be much the same as last year when it comes to financing trends for biotechs. We also cover Emergent's Narcan winning the first over-the-counter approval for an opioid-overdose drug and more of this week's top headlines. |
|
|---|
|
|
Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
Whitepaper This paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
Whitepaper For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
_updated.png)
.png)
